EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Beyond CTLA-4 and PD-1 Inhibition: Novel Immune Checkpoint Molecules for Melanoma Treatment

Dimitrios C Ziogas iD, Charalampos Theocharopoulos, Panagiotis-Petros Lialios iD, Dimitra Foteinou, Ioannis-Alexios Koumprentziotis iD, Georgios Xynos, Helen Gogas iD

Cancers · 11.05.2023 · 15 (10) · 2718

DOI: 10.3390/cancers15102718 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 11.05.2023. Verfasst von Dimitrios C Ziogas und 6 weiteren Autor:innen. Beteiligte Einrichtung: First Department of Medicine, Laiko General Hospital, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece. Die Arbeit wurde bisher 90-mal zitiert (Crossref) und nennt 258 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

More than ten years after the approval of ipilimumab, immune checkpoint inhibitors (ICIs) against PD-1 and CTLA-4 have been established as the most effective treatment for locally advanced or metastatic melanoma, achieving durable responses either as monotherapies or in combinatorial regimens. However, a considerable proportion of patients do not respond or experience early relapse, due to multiple parameters that contribute to melanoma resistance. The expression of other immune checkpoints beyond the PD-1 and CTLA-4 molecules remains a major mechanism of immune evasion. The recent approval of anti-LAG-3 ICI, relatlimab, in combination with nivolumab for metastatic disease, has capitalized on the extensive research in the field and has highlighted the potential for further improvement of melanoma prognosis by synergistically blocking additional immune targets with new ICI-doublets, antibody–drug conjugates, or other novel modalities. Herein, we provide a comprehensive overview of presently published immune checkpoint molecules, including LAG-3, TIGIT, TIM-3, VISTA, IDO1/IDO2/TDO, CD27/CD70, CD39/73, HVEM/BTLA/CD160 and B7-H3. Beginning from their immunomodulatory properties as co-inhibitory or co-stimulatory receptors, we present all therapeutic modalities targeting these molecules that have been tested in melanoma treatment either in preclinical or clinical settings. Better understanding of the checkpoint-mediated crosstalk between melanoma and immune effector cells is essential for generating more effective strategies with augmented immune response.

Schlagwörter

Stichwörter der Autor:innen

LAG-3TIGITTIM-3VISTAimmune checkpoint inhibitorsimmune checkpointsimmunotherapy resistancemelanomarelatlimab

Autor:innen und Institutionen

  • First Department of Medicine, Laiko General Hospital, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece.

ORCID-Profile: Dimitrios C Ziogas, Panagiotis-Petros Lialios, Ioannis-Alexios Koumprentziotis, Helen Gogas

Zitieren

APA

Ziogas, D. C., Theocharopoulos, C., Lialios, P. P., Foteinou, D., Koumprentziotis, I. A., Xynos, G., & Gogas, H. (2023). Beyond CTLA-4 and PD-1 Inhibition: Novel Immune Checkpoint Molecules for Melanoma Treatment. Cancers, 15(10), 2718. https://doi.org/10.3390/cancers15102718

Vancouver

Ziogas DC, Theocharopoulos C, Lialios PP, Foteinou D, Koumprentziotis IA, Xynos G, et al. Beyond CTLA-4 and PD-1 Inhibition: Novel Immune Checkpoint Molecules for Melanoma Treatment. Cancers. 2023;15(10):2718. doi:10.3390/cancers15102718

BibTeX
@article{Ziogas2023,
  author = {Ziogas, Dimitrios C and Theocharopoulos, Charalampos and Lialios, Panagiotis-Petros and Foteinou, Dimitra and Koumprentziotis, Ioannis-Alexios and Xynos, Georgios and Gogas, Helen},
  title = {Beyond CTLA-4 and PD-1 Inhibition: Novel Immune Checkpoint Molecules for Melanoma Treatment},
  journal = {Cancers},
  year = {2023},
  volume = {15},
  number = {10},
  pages = {2718},
  doi = {10.3390/cancers15102718}
}
Kostenlos starten →